Imodium Multi-symptom Reliefloperamide + dimethicone

31,486 adverse event reports submitted to the FDA (1999–2026)

This data reflects voluntary reports submitted to the FDA's Adverse Event Monitoring System (AEMS), formerly the FDA Adverse Event Reporting System (FAERS). A report does not mean the medication caused the event. Data may be incomplete or contain errors. Learn more about AEMS. New to this data? Read our guide on how to interpret FDA adverse event reports →
New to FDA adverse event data? Here's how to read these reports →

Top Reported Adverse Events

The most frequently reported events in association with Imodium Multi-symptom Relief in the FAERS database. These are events reported by patients taking this medication, not necessarily caused by it. A single report may include multiple events.

Show these terms with plain-language definitions

Tap any term below for a plain-language definition.

Browse the full glossary →

Ranked by frequency of reports, not severity. The most-reported event is not necessarily the most dangerous or the most common in patients taking this drug.

Who Is Reporting

Demographics of patients in FAERS reports that included this information. Not all reports include patient demographics.

By Sex

View reporter sex data as a table
Imodium Multi-symptom Relief adverse event reports by reporter sex
SexReports
Female18,273
Male10,766
Unknown21

By Age Group

View age group data as a table
Imodium Multi-symptom Relief adverse event reports by reporter age group
Age groupReports
0-17435
18-341,169
35-492,127
50-645,714
65-745,427
75+4,867

This shows who filed reports, reflecting who takes this drug and who tends to report, not who is at greatest risk.

Reported Outcomes

Outcomes recorded in FAERS reports that included Imodium Multi-symptom Relief. A single report may involve multiple reactions, each with a different outcome. These categories are defined by FDA reporting guidelines, not by PillSignal.

View outcome data as a table
Imodium Multi-symptom Relief adverse event reports by reported outcome
OutcomeReports
Non-Serious12,987
Hospitalization11,088
Other Serious10,667
Death2,511
Life-Threatening1,083
Disability470

Serious outcomes are far more likely to be reported than mild ones, so this overstates how often outcomes are serious. A recorded death does not mean the drug caused it.

Number of FAERS reports received per quarter for Imodium Multi-symptom Relief. Changes in volume may reflect shifts in prescribing rates, media attention, or reporting behavior, not changes in the medication's safety profile.

View report trend as a table
Imodium Multi-symptom Relief adverse event reports by year
YearReports
19993
2004255
2005302
2006321
2007353
2008411
2009423
2010471
2011670
2012874
2013770
2014969
20154,438
20161,909
20172,173
20182,311
20191,988
20202,173
20212,034
20222,146
20232,351
20241,920
20251,827
2026 (partial)394

The steep increase around 2004 reflects the FDA's move to electronic submission, not a change in this drug's safety. Trends track reporting volume, not risk.

Medications commonly reported with Imodium Multi-symptom Relief

In FDA adverse event reports that mention Imodium Multi-symptom Relief, these medications appeared most often in the same report.

This reflects co-occurrence in submitted reports, not evidence of drug interaction or combined risk. People often report several medications taken for the same condition or for unrelated reasons. Talk to a doctor or pharmacist about your specific medications.

Other medications with similar adverse event profiles in FDA FAERS reports.

Data Source

This data is sourced from the FDA's Adverse Event Monitoring System (AEMS), formerly FAERS, via the OpenFDA API. PillSignal is not affiliated with the FDA.

View this data on the FDA website →

Data last updated: June 2026